The preclinical development of human-specific immunotherapeutics such as checkpoint inhibitors is currently hampered by a lack of immunotherapy models featuring human targets in the presence of a functional immune system.
We’ve developed mouse tumor cells engineered to express humanized targets such as PD-L1. You can use these models to evaluate the efficacy of human specific agents targeting humanized proteins expressed on tumor cells.
When combined with humanized GEMM models provides an ideal platform for assessing human specific agents targeting the immune system.
Choose the model that fits your research needs.
These models are fully validated for human protein expression by FACS, as well as ligand and antibody binding.
Choose the HuCELL model that fits your research needs.
Target | Syngeneic Line | Strategy | Mouse Strain |
---|---|---|---|
5T4 | MC38 | Over-expression | C57BL/6 |
B7H3 | MC38 | Over-expression | C57BL/6 |
CCl1 | MC38 | Over-expression | C57BL/6 |
CD19 | EMT6/A20 | Overexpression | BALB/c |
CD20 | A20 | Overexpression | BALB/c |
CD47 | MC38 | KO/Overexpression | C57BL/6 |
CD47/PD-L1 | MC38 | KO/Over-expression | C57BL/6 |
CD73 | MC38 | Over-expression | C57BL/6 |
CEA | CT26.WT | Overexpression | BALB/c |
CLDN18.2 | MC38 | Over-expression | C57BL/6 |
EGFR | CT26.WT | Overexpression | BALB/c |
EpCAM | MC38/CT26.WT | Overexpression | C57BL/6; BALB/c |
GPC3 | CT26.WT | Overexpression | BALB/c |
HER2 | EMT6/MC38 | Overexpression | BALB/c; C57BL/6 |
hPDL1-hFABa | MC38 | Overexpression | C57BL/6 |
PD-L1 | 4T1 | KO/Over-expression | BALB/c |
PD-L1 | B16-F10 | KO/Over-expression | C57BL/6 |
PD-L1 | MC38 | KO/Overexpression | C57BL/6 |
PSMA | RM-1 | Tet inducible | C57BL/6 |
PSMA | MC38 | Over-expression | C57BL/6 |
PVR | MC38 | Over-expression | C57BL/6 |
SIGLEC15 | MC38 | Overexpression | C57BL/6 |
TNFR2 | CT26.WT | Over-expression | BALB/c |
Tell us how we can help
© 2025 Crown Bioscience. All Rights Reserved.
Privacy Policy | Imprint | Terms of Service | Privacy Preferences
© 2025 Crown Bioscience. All Rights Reserved. Privacy Policy
2025-02-21
2021-10-22
site_page